Elon Musk said this week Neuralink plans to begin human implants of Blindsight, the experimental vision chip, within six to 12 months. Khaama Press had him on 24 August. The device is meant to put visual perception back by stimulating visual cortex, not by repairing an eye.

No human Blindsight implantation has been publicly reported. Breakthrough Device designation from the FDA, announced by Neuralink on 17 September 2024, speeds review. It does not mean the implant is approved, safe, or proven. The company lists the work as an upcoming clinical trial: see without eyes.

The engineering idea is old enough to be honest about. Cortical visual prostheses bypass a damaged retina or optic nerve and dump current into visual cortex. People in earlier academic studies have seen phosphenes: points or patterns of light. Turning those sparks into a useful picture is the unsolved part. Musk has said the first version could be low-resolution and improve. He has also said future versions might reach wavelengths outside the human range, infrared and ultraviolet. That last claim is a possibility, not a result. This newspaper will file the trial window, not the superhuman brochure.

Neuralink’s own September 2024 note is one sentence long and specific: Breakthrough Device designation for Blindsight. The company’s updates board still has Telepathy in humans and Blindsight in the future column. Tesorb’s public trial tracker, as of this week, lists Blindsight as pre-clinical, zero implanted, Breakthrough in September 2024, no ClinicalTrials.gov record yet. PRIME is the motor trial. VOICE is speech. CONVOY is the arm. Blindsight is the eyes.

Musk, speaking earlier this year at the Samson International Smart Mobility Summit in Tel Aviv on 18 May, said even someone who had lost both eyes, lost the optic nerve, or was born blind would at first get limited vision, then perhaps precise vision. Tribune Online ran that quote. No implant date was attached then. This week’s six-to-12-month window is the new number. Count from 24 August and you land between February and August 2027 if the window holds. The Standard is not going to pretend a window is a surgery date.

Phosphene field, visual cortex
Phosphene field, visual cortex. A wrap still. No faces.

Telepathy and Blindsight are not the same product wearing a different sticker. Telepathy, on Neuralink’s own description, records from motor cortex — the regions that would have driven hands and arms — and turns that activity into a cursor, a click, a robotic arm. It is a decoder. The 21 Neuralnauts in the 28 January Telepathy post are on that stack: N1 implant, R1 robot, hospital sites, a public enrollment number. Blindsight is meant to write. Electrodes in visual cortex, current in, a phosphene field out, if the claims hold in a human being. One trial reads intention. The other would try to write light. Different cortical real estate. Different indication. Different public record. Twenty-one people on the motor side. Zero Blindsight implants on the page this newspaper can point at.

Neuralink’s public trials board makes the split without a speech. Control devices with your mind: active. Communicate with your thoughts: active. See without your eyes: upcoming. Upcoming is the word. It is not recruiting. It is not NCT-anything. ClinicalTrials.gov, which carries PRIME and VOICE as rows with start dates and sites, does not yet carry a Blindsight protocol that this desk can file. Tesorb said the same: not yet registered. If a first-in-human later appears as a registry row, that row will be the news. It is not the news tonight.

The 17 September 2024 Breakthrough tag is real and it is limited. Reuters, the same day, explained the program: the FDA gives the designation to certain devices aimed at life-threatening or irreversibly debilitating conditions, and the point of the tag is to speed development and review. Neuralink’s own announcement was a sentence. Breakthrough is not an Investigational Device Exemption. It is not a marketing authorisation. It is not a finding that Blindsight is safe in a person. Engadget, filing the same designation, noted that manufacturers in the program get more contact with FDA reviewers and that breakthrough devices are prioritised in the queue. Priority in a queue is not a surgery. Keep the label on.

Human implants of an investigational implant in the United States still need a study that regulators have actually cleared. Neuralink has that clearance, on the public record, for Telepathy’s PRIME work and for VOICE. It has not, on the public record this newspaper is holding, put a first Blindsight volunteer under the robot. Khaama Press, on 24 August 2026, said Musk has previously said the technology has been tested in monkeys. That is a preclinical claim, attributed. This page is not going to invent a primate count, a paper, or a photograph of an animal. Pre-clinical is Tesorb’s word for the program. Zero implanted is Tesorb’s other word. Both still match the empty human column.

Musk’s medical claims for the device should stay labelled as claims. Reuters, 17 September 2024, had him saying Blindsight “will enable even those who have lost both eyes and their optic nerve to see.” Engadget quoted the proviso: provided the visual cortex is intact, it would even enable people blind from birth to see for the first time, on his telling. Limited vision first, perhaps precise vision later, is the May line from Tel Aviv. Infrared, ultraviolet, radar wavelengths are the brochure at the far end. None of that is a result in a human Blindsight recipient, because there is not one on the public record. Phosphenes in earlier academic cortical work are the honest precedent. Sparks of light are not a street, a face, or a page of type.

The window itself is a pair of months, not a calendar appointment. Six to 12 months from 24 August 2026 is February 2027 at the near end and August 2027 at the far end. Khaama dated the remark 24 August. Dim Sum Daily and other secondary write-ups of an earlier August remark used the same six-to-12-month span; this file takes Khaama’s date as the one on the week. If the window slips, the next file is the slip. If a first implant is posted, the next file is a name, a site, and a registry number. Tonight the facts are Musk’s window, Neuralink’s 17 September 2024 Breakthrough sentence, Tesorb’s zero, and the company’s own “upcoming trial” line.

Regulatory path, as a sequence this newspaper will not skip: a Breakthrough designation, then a cleared investigational study, then a first-in-human, then a primary safety follow-up, then whatever efficacy measure the protocol actually names. Telepathy had to walk that corridor. VOICE is walking it with six people listed and a Dallas site. Blindsight is still in the first room. A visual prosthesis that writes to cortex is a harder clinical object than a cursor decoder, which is why the empty column is not an insult. It is the state of the file.

This desk will not print a living face for a trial that has not named a recipient. The wrap still is a phosphene field, visual cortex, no faces. Newspaper wrap, not a full-bleed of a skull. The robot and the model can sit in the well. They are not a patient. They are not a result.

File the window. Six to 12 months, Musk, 24 August 2026, via Khaama Press. Breakthrough Device designation, Neuralink, 17 September 2024. Zero human Blindsight implants on the public record. No ClinicalTrials.gov row yet. Telepathy is the motor trial with 21 people on Neuralink’s January post. VOICE is speech. Blindsight is the eyes, and the eyes are still upcoming. February to August 2027 if the window holds. A window is not a surgery date.